NEUROLONIC

Our Purpose

Neurolonic exists to make emotional intelligence measurable, continuous, and accessible at scale — enabling everyday emotional awareness and support without appointments, clinical bottlenecks, or gatekeeping, while remaining compatible with clinical and enterprise systems when required.

Where We Are Today

• Core AI platform in final refinement (stability, accuracy, real-world usability)
• D2C product nearing launch readiness
• Licensing and B2B pathways prepared in parallel
• Operations active across the U.S., U.K., and Europe

Neurolonic is structured to support consumer-scale access and institutional deployment without overextension.

Capital & Structure

• U.S. (Delaware) and U.K. entities incorporated
• $20,000 SAFE secured and in final closing stage
• SAFE capital allocated toward product acceleration, launch readiness, and early validation

Capital History (Pre-SAFE)

Neurolonic has been built over multiple years with a combination of founder capital and early investor support:

• Founder capital: ~€150,000 deployed (2017–2025)
• Mr. Balamurali: ₹20 lakhs (2023–2025)
• Mr. Karthik Sundaram: €20,000 (2020–2024)
• Ms. Kiruba: £14,100 (2024–2025)
• Mr. Jaysankar: ₹5 lakhs Debt(2025–2026)
• Other early investors: ~€50,000 (2018–2025)

This capital supported early research, validation, product development, and foundational infrastructure ahead of the current commercial execution phase.

Advisory & Execution Support

• U.S. market entry and commercial positioning
• Early B2B and institutional engagement pathways
• Product validation, pilots, and go-to-market sequencing

Current advisors include (selected list):

• Tom White – U.S. Sales Strategy & Advisory
• Ryan Steller – Investor communications & early-stage ecosystem alignment

Advisory involvement is scoped, milestone-aligned, and integrated alongside internal execution. Detailed milestone definitions and equity mechanics are being finalized in parallel with execution.

Launch Window

• Mid-February 2026: Final AI version
• Late February / Early March 2026: Initial public launch (mobile + web)

Current Focus

• Usability over breadth
• Feedback over scale
• Controlled growth

Next 6 Months: Execution Priorities

1. Product & Technology

• Improve emotion and mental-state detection
• Deploy real-world feedback loops
• Hardware (ring → earbud) progresses alongside software, not as dependencies

2. Market Adoption

• Gradual D2C growth targeting ~5,000 users
• Direct B2B engagement across the U.S. & U.K., targeting ~10 institutional partners
• Early pilots with healthcare, wellness, and research organizations

3. Team & Operations

• Lean, purpose-driven team expansion
• Strong documentation and compliance discipline
• Internal milestones over artificial deadlines

Operating Philosophy

• Direction
• Execution discipline
• Transparent communication

Progress is measured by what is built, released, and used.

Potential Obstacles (Actively Managed)

• Early user retention
• Regulatory & compliance timelines
• Capital pacing

Current Asks

Neurolonic is selectively engaging with:

• Strategic collaborators
• Capital partners

We prioritize relationships that accelerate learning, strengthen delivery, and reinforce long-term trust.